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ABSTRACT 
The oral solid dosage forms are extremely relevant to drug therapy and responsible for much of the pharma-
ceutical industry turnover worldwide. However, the development of medicines in solid form involves signifi-
cant challenges, including obtaining formulations with appropriate bioavailability for low aqueous solubility 
drugs (classes II and IV of the Biopharmaceutics Classification System). One of the most effective strategies 
to overcome poor dissolution rate and low absorption of drugs is the solid dispersion technique, however, 
although it has been the focus of much research in recent decades, there are relatively few commercially 
available products based on such technology. This is mainly due to problems related to production scale-up 
and physicochemical instability and creates opportunities for new studies to explore the full potential of the 
technology. This review presents an overall approach to the factors affecting the dissolution rate and oral 
bioavailability of BCS-classes II and IV drugs and a brief review of the state-of-the-art of solid dispersion 
technology. 
Keywords: oral delivery, drug solubility, drug dissolution, solid dispersion. 
1. INTRODUCTION 
The oral route is the most commonly used for drug administration due to significant inherent advantages 
compared to other routes, such as safety, non-invasive nature, convenience and comfort to the patient, possi-
bility of self-administration and systemic distribution of the drug. Among all types of oral dosage forms, the 
solid ones, such as tablets and capsules, are the most used in therapy, because they offer many benefits, such 
as simplicity and low cost of production, high stability, convenience of the presentation in unit doses, porta-
bility, ease of administration and masking the unpleasant taste of many drugs [1,2].  
 A major obstacle to the development and large-scale production of oral solid dosage forms is the low 
solubility of many drugs, given the negative effect that this property has on drug absorption and bioavailabil-
ity. Concern about drug solubility in the pharmaceutical industry has intensified from the 90s, when the use 
of techniques, such as combinatorial chemistry and high throughput screening (HTS), increased the achieve-
ment of new chemical entities with high molecular weight and high lipophilicity [3, 4]. Recognizing that drug 
dissolution and gastrointestinal permeability are the fundamental parameters controlling the rate and the ex-
tent of drug absorption grounded the proposition of the Biopharmaceutical Classification System (BCS) for 
correlating drug product in vitro dissolution and in vivo bioavailability, in which classes II and IV encompass 
drugs with low solubility [5, 6, 7]. 
 The need for effective formulations for BCS-classes II and IV drugs led to the progress of knowledge 
in the area of drug delivery systems for oral administration, over the years, and to the development of various 
technological strategies to remedy unsatisfactory biopharmaceutical properties, for example, micronization 
[8], formation of complexes with cyclodextrins [9], self-emulsifying drug delivery systems (SEDDS) [10], 
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liquisolid systems [11, 12] and solid dispersions [13, 14]. 
 Large investments in research and development of solid dispersions brought good results for the 
pharmaceutical industry, with the emergence of products based on this technology on the market. Neverthe-
less, there is still plenty of room for improvement, aiming to overcome some limitations of the solid disper-
sion technology. Additional studies for development and improvement are still needed regarding the produc-
tion processes, carrier materials and stabilization strategies, so that the full potential of solid dispersions is 
explored, thus resulting in increased number of commercially available products [13,15]. This review pre-
sents an overall approach to the factors affecting the dissolution and oral bioavailability of BCS-classes II 
and IV drugs and a brief review of the state-of-the-art of solid dispersion technology. 
2. ORAL ADMINISTRATION OF POORLY WATER-SOLUBLE DRUGS 
For producing the desired pharmacological response after oral administration, as shown in Figure 1, a dosage 
form must release the drug in the gastrointestinal tract to be absorbed, reach the systemic circulation, and be 
distributed in the site of action in the body at sufficient rate and extent [16, 17]. The term bioavailability re-
fers to the rate and extent at which the active drug reaches the systemic circulation [17, 18, 19]. Many factors 
may influence the bioavailability of drugs, which may be related to the dosage form, the manufacturing pro-















Figure 1: Steps involved in the release from a solid dosage form and gastrointestinal absorption of a drug [17]. 
2.1 Factors affecting drug bioavailability: related to the pharmaceutical dosage form and to the manu-
facturing process 
The dosage form needs to undergo several steps after oral administration to occur the release of the drug, and 
for making it bioavailable. Factors and characteristics related to the dosage form itself may interfere with 
drug release, for example, the manufacturing process, the nature of the excipients, the disintegration time and 
the drug release rate [20, 21, 22, 23]. 
 The manufacturing processes can subject the components of the formulation to mechanical or thermal 
stress, which can induce phase transitions of certain drugs (interconversion of polymorphs, solvates/hydrates 
or amorphous form), thereby altering their chemical, physical, mechanical and biopharmaceutical (drug dis-
solution and bioavailability) properties. Examples of manufacturing operations that can trigger polymorphic 
transformations are granulation, spray drying, grinding, mixing, compression, encapsulation, and coating [21, 
22, 23]. 
 The selected excipients and processing operations can influence the disintegration properties of the 
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dosage form and therefore the drug dissolution profile and bioavailability. The greater the rate of disintegra-
tion of the dosage form, the more rapidly the drug can progress to the steps of dissolution and absorption. 
Excipients possessing favorable characteristics of compactness, for example, allow the replacement of the 
wet granulation process by direct compression, the last usually resulting in tablets with faster disintegration. 
Also, using water-soluble and swellable excipients favors the disintegration of the dosage form and drug re-
lease, and, on the contrary, the use of insoluble excipients may hinder the disintegration and dissolution steps 
[20, 21, 22, 23]. 
2.2 Factors affecting drug bioavailability: related to the drug 
Factors inherent to the drug itself that influence its absorption and bioavailability include physicochemical 
properties (e.g. solubility, stability, polymorphism); solid state (amorphous, crystalline); particle size; 
transport across intestinal membrane; and metabolism [21, 22, 24]. 
 The drug must be dissolved in the gastrointestinal environment to be then absorbed. The solubility of 
the drug is the main limiting factor for its dissolution, as the aqueous nature of the gastrointestinal contents 
causes poorly-water soluble drugs to present low saturation solubility and thus a lower dissolution rate [6,19]. 
The main drug absorption mechanism in the gastrointestinal tract (GIT) occurs by passive diffusion; therefore, 
the absorption is favored when the drug is presented in the non-ionized state, in its more lipophilic form, 
which enables the permeation through cell membranes [25]. 
 Particle size may influence drug bioavailability, i.e., the smaller the particle size, the larger the surface 
area of the substance in contact with the dissolution medium, and thus the higher the dissolution rate and the 
absorption of the drug [8, 26]. 
 The amorphous form of a drug can lead to improved bioavailability compared to the crystalline form. 
Crystalline solids are those in which atoms, ions or molecules have a periodic arrangement, that is, that re-
peats regularly in the three dimensions. Amorphous solids don’t have long-range spatial ordering, tend to be 
more energetic than crystalline ones, and therefore usually have distinct physicochemical properties, such as 
higher solubility and higher dissolution rate. Although they exhibit inferior solubility and dissolution proper-
ties, crystalline drugs are more frequently used in pharmaceutical formulations because amorphous ones gen-
erally exhibit lower physical and chemical stability, with a tendency to crystallization and degradation [24]. 
 Polymorphism affects the solubility, the stability, the dissolution rate and the bioavailability of drugs. 
Polymorphs are crystalline phases containing the same molecules but having different conformations and/or 
packing arrangements in the solid-state. Although these molecules are chemically identical, the polymorphs 
have different physicochemical properties such as melting point, solubility and hygroscopicity. Anhydrous 
forms of drugs, for example, have a higher thermodynamic activity compared to the corresponding hydrates, 
and, consequently, increased solubility and dissolution rate. Different polymorphic forms can arise from the 
conditions employed in the synthesis and purification of the drug, depending, for example, on the type of 
solvent used and the reaction temperature [24, 27, 28]. 
 Once absorbed, the drug passes through the liver and may undergo metabolization or biliary excretion 
before reaching the systemic circulation and being delivered to the site of action. When this capacity of the 
liver to metabolize and excrete the drug is high, the bioavailability is significantly reduced; this phenomenon 
is called first-pass metabolism. Therefore, the amount of drug that reaches the systemic circulation depends 
not only on the administered dose but also to the fraction of this dose that is absorbed and passes unchanged 
through the liver, without suffering any first-pass effect. This fraction is the amount of drug that is bioavaila-
ble to perform its therapeutic function [25]. 
 After metabolization, the unchanged fraction of the drug is distributed by the blood to the tissues 
where it will exert the pharmacological effect. Many substances circulate in the bloodstream bound to plasma 
proteins, mainly albumin. This binding to plasma proteins limits the distribution of the drug, as only the free 
fraction is able to cross membranes and reach the site of action [25]. 
2.3. Low solubility drugs (BCS classes II and IV) 
In recent years, there has been an increase in developing drugs with high molecular weight and lipophilicity. 
As a result, approximately 40% of drugs with market approval and about 90% of molecules in the discovery 
pipeline show low water solubility [29].  
 Low dissolution rate arising from poor solubility frequently leads to low bioavailability of orally ad-
ministered drugs, thus resulting in limited therapeutic potential and unsatisfactory clinical outcomes [6,30]. 
In some cases, dose escalation becomes necessary to allow therapeutic concentrations of the drug to be 
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reached in the blood, which can lead to topical toxicity in the GIT and negatively affect patient adherence to 
treatment [6]. 
 A useful decision-making tool in the development of oral pharmaceutical formulations is the Bio-
pharmaceutics Classification System (BCS), proposed by Amidon et al., in 1995, which categorize the drugs 
based on their water solubility and intestinal permeability [5, 7, 31]. 
 BCS categorizes drugs into four classes, namely: class I (high solubility and high permeability), class 
II (low solubility and high permeability), class III (high solubility, low permeability) and class IV (low solu-
bility and low permeability) [5,7]. For classification purposes, American regulatory body Food and Drug 
Administration (FDA) considers a highly soluble drug when the highest dose strength is soluble in < 250 ml 
of water over a pH range of 1 to 7.5. A drug substance is considered highly permeable by FDA when the ex-
tent of absorption in humans is determined to be > 90% of an administered dose, based on mass-balance or in 
comparison to an intravenous reference dose [31]. 
 Drugs with a low water solubility (BCS-classes II and IV) have great potential for low bioavailability 
when administered in oral solid dosage forms. Dissolution is the limiting step for BCS-class II drugs absorp-
tion, which is impaired due to the low water solubility of the compound. While these drugs are highly perme-
able, the low solubility produces a low concentration gradient between the intestine and the bloodstream, 
limiting transport across the biological membranes and absorption. Besides low solubility, BCS-class IV 
drugs have low permeability as an additional factor that hinders the absorption [5, 7, 31]. 
3. SOLID DISPERSIONS 
A solid dispersion is a dispersion, in the solid state, of a drug (or more than one) in a matrix formed by a hy-
drophilic carrier (or by an association of carriers). Solid dispersion technology has been successfully applied 
in the development of formulations aimed at the improvement of the dissolution profile and bioavailability of 
poorly water-soluble drugs [13, 32, 33, 34, 35, 36, 37]. Mechanisms that can be involved are the reduction of 
drug particle size, possibly down to the molecular level; the increased wettability of the drug; formation of 
soluble drug-carrier complexes; and amorphization of the drug [13,34]. It is important to mention that solid 
dispersions are intermediate products that have to be incorporated in a final dosage form, such as capsules or 
tablets [13]. Some examples of commercially available pharmaceutical products based on solid dispersion 
technology are listed in Table 1. 
Table 1: Examples of commercially available pharmaceutical products based on solid dispersions. 
TRADE NAME MANUFACTURER DRUG CARRIER DOSAGE FORM 
Afeditab CR Actavis Nifedipine Poloxamer/PVP Tablet 
Certican Novartis Everolimus HPMC Tablet 
Crestor AstraZeneca Rosuvastatin HPMC Tablet 
Fenoglide Salix  Fenofibrate PEG Tablet 
Gris-PEG Pedinol  Griseofulvin PEG  Tablet 
Incivek Vertex  Telaprevir HPMCAS Tablet 
Incivo Janssen  Telaprevir HPMCAS Tablet 
Intelence Janssen Etravirine HPMC Tablet 
Isoptin SR-E Abbott Verapamil HPC/HPMC Tablet 
Kaletra  Abbott Lopinavir, ritonavir PVPVA Tablet 
Kalydeco Vertex  Ivacaftor HPMCAS Tablet 
Nimotop Bayer Nimodipine PEG Tablet 
Nivadil Fugisawa  Nilvadipine HPMC Tablet 
Noxafil Merck Posaconazole HPMCAS Tablet 
Norvir Abbott Ritonavir PVPVA Tablet 
Onmel Stiefel Itraconazole HPMC Tablet 
Prograf Fugisawa  Tacrolimus HPMC Capsule 
Sporanox Janssen Itraconazole HPMC Capsule 
Zelboraf Roche Vemurafenib HPMCAS Tablet 
Zortress Novartis Everolimus HPMC Tablet 
HPMC: hydroxypropyl methylcellulose; HPMCAS: hydroxypropyl methylcellulose acetate succinate; HPC: 
hydroxypropyl cellulose; PEG: polyethylene glycol; PVP: polyvinylpyrrolidone; PVPVA: polyvinylpyrrolidone-co-
vinyl acetate. 
[13, 33, 35, 36, 37]. 
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 Although the number of components is not limited to two, solid dispersions usually are binary systems 
in which the drug and the carrier can exist in different arrangements (Figure 2): (A) the drug is molecularly 
dispersed in the matrix formed by the carrier; (B) crystalline drug particles are dispersed in the carrier matrix; 























Figure 2: Possible arrangements between drug and carrier in polymeric solid dispersions: (A) the drug is molecularly 
dispersed in the matrix formed by the polymeric carrier; (B) the drug in the crystalline state is dispersed in the polymeric 
matrix; (C) domains rich in amorphous drug are dispersed in the polymeric matrix [33]. 
 Solid dispersions are classified in eutectic mixtures, solid solutions, glass solutions, or glass suspen-
sions [35] whose definitions and mechanisms for drug dissolution improvement are presented in Table 2. 
Solid dispersions are also classified into four generations based on the advancement of knowledge and com-
plexity of the system [13] as compared in Table 3 and described in 3.1. 
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Table 2: Categories of solid dispersions: state of the drug, number of phases, definitions, and mechanism involved in 









MECHANISM FOR DRUG 
DISSOLUTION ENHANCE-
MENT 
Solid solution Crystalline 01 
Solution formed by the incorpo-
ration of the drug molecules 
into the crystal lattice of the 
carrier. 
The particle size of the drug is 





Mixture of two compounds that 
are completely miscible in the 
liquid state (melt) but show 
limited miscibility in the solid-
state form. At a specific compo-
sition, the two components 
crystallize simultaneously when 
the temperature is reduced. 
Once in contact with aqueous 
GIT fluids, the carrier dis-
solves rapidly and release fine 
crystals of the drug. Drug 
dissolution rate is enhanced 
due the large surface area and 
the improved wettability from 
the carrier. 
Glass solution Amorphous 01 
Solution where the drug is dis-
persed molecularly in the amor-
phous carrier. 
The particle size of the drug is 





Suspension containing the drug 
in a separate amorphous phase 
dispersed in the amorphous 
carrier. 
The drug dissolution rate is 
still increased compared to 
the crystalline form of the 
drug since the drug is still in 
the amorphous state in the 
glass suspension. 
[35]. 
Table 3: Characteristics of the four generations of solid dispersions. 
 SOLID DISPERSION GENERATION 
 First Second Third Fourth 





mer or swellable pol-
ymer 
Main properties 
- Lower dissolution 
rates compared to 2nd 
generation due to 
crystalline carrier 
- Low stability 
- Higher drug dissolu-
tion rates compared to 
1st generation 
- Precipitation under 
supersaturation 
- Low stability 





- Increased stability 




3.1 Generations of solid dispersions 
3.1.1 First-generation solid dispersions 
The first description of a solid dispersion was a eutectic mixture of sulfathiazole and urea by Sekiguchi and 
Obi in 1961 [34, 38, 39]. In this same decade, the use of the technique has been described for other drugs 
giving rise to the so-called first-generation solid dispersions, or crystalline solid dispersions, characterized by 
the use of crystalline carriers [13,34]. Crystalline carriers can form solid dispersions that are eutectic mix-
tures (the melting point of the mixture is lower than the melting point of the drug and carrier), monotectic 
mixtures (the melting point of the carrier and drug are constant) or interstitial solid solutions (drug molecules 
occupy the interstitial spaces between the solvent molecules in the crystal lattice) [13, 40]. Eutectics are more 
preferable (as compared to monotectics) because both the drug and carrier crystallize simultaneously in the 
cooling process, resulting in a well-dispersed state of the drug in carrier [13].   
 Examples of crystalline carriers used in solid dispersions are urea, organic acids (e.g. citric acid and 
succinic acid), and sugars (e.g. mannitol, xylitol, sucrose, dextrose, and galactose) [40]. 
 The main disadvantage of the first generation solid dispersions is the high thermodynamic stability of 
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the carrier, which promotes lower dissolution rates compared with amorphous solid dispersions [13, 34]. Al-
so, the high melting point of some carriers used in crystalline solid dispersions complicates the preparation of 
such systems by the melting method [13,14]. Urea, organic acids, and most sugars (mannitol is an exception) 
are thermally unstable; therefore, they are unsuitable for solid dispersion preparation by the melting method. 
In addition, obtaining solid dispersions by solvent-based process using sugars as carriers is infeasible because 
they are poorly soluble in nonaqueous solvents and also are unable to retard drug crystallization during sol-
vent evaporation [40]. 
3.1.2 Second-generation solid dispersions 
A second generation of solid dispersions was developed using amorphous carriers, which are mostly poly-
mers [13, 33, 34]. Such solid dispersions, called amorphous solid dispersions, may be classified as glass solid 
solutions, glass suspensions or a mixture of both, according to the physical state of the drug [13, 34]. As stat-
ed in Table 2, in glass solutions, the drug and the carrier are completely miscible, so that they form a homo-
geneous molecular mixture, while glass suspensions consist of two separate phases [13, 35]. Glass suspen-
sions are formed when the drug has a limited solubility in the carrier or an extremely high melting point [13, 
35].  
 Some examples of polymers used in second generation solid dispersions are polyvinylpyrrolidone 
(PVP), crospovidone, polyvinypyrrolidone-co-vinylacetate (PVPVA), polymethacrylates, cellulose deriva-
tives [e.g. hydroxypropylcellulose (HPC), hydroxypropylmethyl cellulose (HPMC), hydroxylpropylmethyl-
cellulose acetate succinate (HPMCAS), hydroxypropylmethylcellulose phthalate (HPMCP), ethylcellulose 
(EC)], starch and cyclodextrins] [13, 34, 41]. 
3.1.3 Third-generation solid dispersions 
Amorphous drugs can recrystallize from solid dispersions during obtaining process (cooling or removal of 
solvent) or storage, and also can precipitate after the achievement of a supersaturation state in vivo, adversely 
affecting drug bioavailability. Therefore, the main objective in formulating third-generation solid dispersions 
is to overcome problems related to drug recrystallization and precipitation [13, 34]. 
 Third-generation solid dispersions contain surfactants, self-emulsifiers, or mixtures of amorphous pol-
ymers and surfactants as carriers. The addition of surfactants in the solid dispersion can improve drug disso-
lution by increasing drug wettability and solubility. Surfactants also improve the physical stability of solid 
dispersions because they aid in drug-polymer miscibility and reduce drug recrystallization. Furthermore, the 
use of surfactants in solid dispersions can prevent drug precipitation in the aqueous medium. However, cau-
tion must be employed in selecting the surfactant because in some cases it can interact with polymer and 
thereby increase drug recrystallization [13, 34, 42].  
 Examples of surfactants used in third-generation solid dispersions are poloxamer 407, poloxamer 188, 
Compritol
®




 SP1 [13,34], Soluplus
®
, sodium lauryl sulfate (SLS), poly-
sorbate 80, polyoxyethylene hydrogenated castor oil [34, 42]. 
3.1.4 Fourth generation solid dispersions 
The fourth-generation of solid dispersions encompasses sustained-release (or controlled-release) systems 
containing drugs with low water solubility and short plasma half-life. The drug dispersed molecularly in the 
carrier becomes more soluble in aqueous media whereas insoluble or swellable polymers are used to sustain 
the drug release in the dissolution medium [13]. The hydrophilic and swellable properties of swellable poly-
mers make them ideal carriers for sustained-release solid dispersions because they have two advantageous 
functions in nature: improving drug solubility and sustaining drug release (by swelling, diffusion and erosion 
mechanisms) [43]. 
 The benefits of fourth-generation solid dispersions include those typical of sustained-release drug de-
livery systems, i.e., reduced dosing frequency, reduction of side effects, and improved adherence to the 
treatment by the patient [13]. 





 RL, poly(ethylene oxide) [PEO], carboxyvinyl polymer (Carbopol
®
) [13],  sodium carboxymethyl-
cellulose (Na-CMC), and HPMC [43].  
3.2 Stabilization of solid dispersions 
Drugs in the amorphous state have higher molecular mobility and increased thermodynamic properties, 
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which confers to them higher apparent water solubility, dissolution rate, and oral absorption when compared 
to crystalline forms. However, these thermodynamic characteristics are the same that provides lower chemi-
cal and physical stability. Therefore, pure amorphous drugs are rarely used in pharmaceutical formulations 
due to their inherent higher reactivity and tendency to convert to a stable crystalline form. On the other hand, 
the solubility advantage of the amorphous form can be retained if the amorphous drug is stabilized into a ma-
trix of excipient(s) in the form of a solid dispersion [36, 44]. 
 Amorphous solid dispersion, wherein a crystallizable, small molecule drug disperses in an amorphous 
polymer matrix, is one of the most promising and viable formulation strategies for poorly water-soluble drugs 
[45]. For the success of such strategy the drug in the solid dispersion needs to remain in the amorphous state 
during manufacture operations; storage; and also after the intake by the patient, without recrystallization of 
the supersaturated solution formed in the gastrointestinal fluids [36, 44].  
 Drug recrystallization can be avoided in amorphous solid dispersion by minimizing molecular mobili-
ty and forming an energetic barrier to thermodynamic reactions. The stabilization mechanisms can involve: a 
physical barrier to crystallization; reduction in the chemical potential of the drug; anti-plasticization; and 
drug-polymeric interactions [36, 44, 45] as explained in Table 4. 
Table 4: Mechanisms involved in the stabilization of amorphous solid dispersions. 
MECHANISM OF STABILIZATION EXPLANATION 
Physical barrier to crystallization 
Phase separation and crystallization of amorphous materi-
als demand diffusion and nucleation, both phenomena 
involving molecular mobility. The incorporation of drug 
molecules (amorphous drug) into the network formed by 
the polymeric carrier in an amorphous solid dispersion 
hinders the molecular mobility of the drug and reduces its 
tendency to crystallization.   
Reduction in the chemical potential of the drug 
Amorphous drugs have high chemical potential, which acts 
as a driving force for crystallization. Mixing the amor-
phous drug with a polymer, forming a miscible amorphous 
system, lowers the chemical potential of the drug and its 
tendency to crystallize. 
Anti-plasticization 
Using a polymer with high Tg (glass transition tempera-
ture) as carrier increases the Tg of the amorphous solid 
dispersion as compared to the Tg of the drug, which in-
creases the free energy required by the amorphous drug to 
convert into the crystalline form. 
Drug-polymer intermolecular interactions 
Formation of intermolecular interactions (ion-dipole inter-
actions and intermolecular H-bonding) between the drug 
and the polymeric carrier blocks drug-drug interactions 
that can form the crystal lattice. 
[36, 44, 45]. 
3.3 Preparation methods 
The classic methods described in the literature for preparing solid dispersions are the fusion method, the sol-
vent method and the fusion solvent method. The two first are the most common and manufacturing processes 
fusion-based and solvent-based are available for industrial applications [13]. Mechanical processes such as 
ball milling or grinding can also be used but the degree of amorphization is usually lower in comparison with 
fusion and solvent methods [13, 14, 35, 36, 46]. The main obtaining methods for solid dispersions are briefly 
described below and their advantages and limitations are presented in Table 5. 
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Table 5: Advantages and limitations of methods used for preparing solid dispersions. 
PREPARATION METHOD ADVANTAGES LIMITATIONS 
Fusion-based - Solvent free 
- Use of high temperature 
- Drug and carrier have to be miscible 
at the heating temperature 
- Drug and carrier have to be thermal-
ly stable at the heating temperature 
Solvent-based 
- Applicability for thermo labile drugs 
and carriers because it does not re-
quire high temperature 
- Enables the use of high-melting 
point carriers, which can not be used 
in fusion method 
- Difficulty of selection of a solvent 
capable of solubilizing both the hy-
drophobic drug and the hydrophilic 
carrier 
- Generation of toxic residues 
- The need to evaporate a large 
amount of the solvent makes the pro-
cess expensive 
Fusion-solvent method 
- Temperature and mixing time are 
lower than in fusion method, thus 
protecting the drug from thermal deg-
radation 
- The carrier in the molten state is 
more easily dispersed and dissolved in 
the solvent in comparison with solvent 
method 
- Limited application with few reports 
in literature compared to other meth-
ods 
Co-grinding 
- Solvent free  
- Environmentally friendly 
- Low cost, simple equipment, easy to 
scale up 
- Grinding can result in a mixture of 
amorphous and nanocrystalline drug, 
and the last can act as seeds to induce 
drug nucleation and recrystallization 
[13, 14, 34, 35, 36, 47, 48, 49]. 
3.3.1 Fusion method 
In the fusion method (or melting method), drug and carrier are heated together to the lowest temperature 
above the melting points of them both, or the drug is incorporated into the melted carrier, the mixture remains 
under heating until a homogeneous solution is obtained then it is cooled rapidly. For cooling and solidifica-
tion of the molten mixture, various techniques may be used, such as agitating in an ice bath; placing in a 
freezer; spreading a thin layer on stainless steel and cooling by air or water; immersion in liquid nitrogen; 
among others. The final mass is crushed, pulverized and sieved [13, 14, 35, 36, 46]. 
 Fusion-based processes available at industrial scale involve melt agglomeration or melt extrusion [13, 
35, 46]. Melt agglomeration processes use standard granulation equipment (e.g. high shear mixer or fluid bed 
dryer), where a melted mass of drug and carrier(s) is added to the powdered excipients of the formulation as a 
granulation liquid. The molten material ensures the adsorption of the drug and carrier(s) on the powdered 
excipients and the resultant granules are then processed to obtain the final dosage form [46]. 
 In hot melt extrusion, the material (drug and polymer) melts under high temperature and is further 
forced through a die with the help of one or two conveyor screws in a barrel, resulting in a product of uni-
form shape. Individual components within the extruder are the feed hopper, a temperature controlled barrel, a 
conveying system for material transport and mixing (one or two rotating screws), a die, and heating and cool-
ing systems. Cooling of the material can be done by air, water or by a contact with a cold surface. The extru-
sion process can result in the formation of strands or films, which can be cut to the required size, an also can 
be executed using specific downstream equipment setups, which produce dosage forms such as pellets, gran-
ules, spheres and tablets [50, 51]. This technique is simple, efficient, and offers the possibility of continuous 
manufacture, which makes it one of the most employed industrial solid dispersion manufacturing process. 




3.3.2 Solvent method 
In the solvent method, the drug and the carrier are solubilized in a common solvent, which is then removed 
yielding a solid dispersion. Such technique enables dispersion in a molecular level that is preferred to en-
hance the solubility and stability of the product. Solvent removal may be accomplished by several methods, 
such as vacuum drying, rotary evaporation, freeze-drying, or spray drying [13, 36, 46]. Commonly used sol-
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vents are methanol, ethanol, ethyl acetate, acetone, methylene chloride, water, among others [13, 46]. 
 Spray drying is widely applied in pharmaceutical industry to prepare solid dispersions due to the pos-
sibility of continuous manufacturing, ease of scalability, and cost-effectiveness [13, 52]. The spray drying 
process is used to convert a solution or suspension of a drug and a carrier into a dry powder (amorphous solid 
dispersion) in a single step [15,36] and involves: (1) the feed solution/suspension is pumped into the drying 
chamber through a nozzle; (2) the droplets are atomized and come in contact with the drying fluid (hot gas, 
often air) inside the drying chamber; (3) the dried material is separated from the drying medium using a cy-
clone and is collected in a collection device; (4) the exhaust gases are filtered via HEPA filters [52,53]. Car-
riers used in solid dispersions prepared by spray drying are generally the same used in those obtained by fu-
sion methods, including metacrilates, PVP and derivatives, HPMC and HPMCAS [46, 52, 53]. 
3.3.3 Fusion-solvent method 
The fusion-solvent method is a combination of the fusion and the solvent methods consisting in heating the 
carrier to a temperature above its melting point; dissolving the drug in a suitable solvent; incorporating the 
drug solution in the molten carrier under stirring; removing the solvent, cooling and solidification to form the 
solid dispersion [13].  
3.3.4 Co-grinding method 
In grinding operation, mechanical energy is applied to physically break down coarse particles into finer ones. 
When particle size reduction reaches a critical threshold (limit beyond which the material becomes difficult 
to comminute even prolonging the grinding time), the continued transfer of mechanical energy to the drug 
leads to partial or complete amorphization [26]. However, drug particles <30 μm produced by grinding have 
large surface/interfacial area, increased free energy and decreased thermodynamic stability, which can pro-
mote particle agglomeration. Also, amorphous material may be thermodynamically unstable, leading to 
amorphous-crystalline inter-conversions of the drug. Both agglomeration and recrystallization phenomena 
decrease drug dissolution rate and bioavailability. Co-grinding drugs together with certain excipients, result-
ing in solid dispersions, can reduce particles agglomeration and drug recrystallization [35, 26]. 
 Examples of carriers employed for preparing solid dispersions by co-grinding in a ball mill are: PVP, 
crospovidone and microcrystalline cellulose [47]; chitosan [48]; sodium alginate [49]; and poly(vinyl alco-
hol) (PVA) [54]. 
3.4 Technological issues in industrial production 
Solid dispersions may have scaling-up problems when conventional dosage form manufacturing processes 
are taken into account. The typical soft and tacky characteristics of solid dispersions may result in deficient 
properties of flow, mixing and compaction, leading to low reproducibility of the physical properties of the 
final products. Also, the thermal, chemical and mechanical stress applied during processing can induce insta-
bility by degradation or recrystallization mechanisms [14]. Although a current need to develop production 
processes and scale them up to industrial level in a reliable manner still exist, different manufacturing pro-
cesses are being developed to obtain solid dispersions with adequate robustness and reproducibility [46]. 
4. CONCLUSIONS 
The pharmaceutical industry is one of the most profitable industries worldwide and oral solid dosage forms 
are responsible for most of the drug prescriptions. However, as shown in this work, the development of new 
pharmaceutical formulations poses certain difficulties, including the achievement of adequate bioavailability 
for poorly water-soluble drugs. Accordingly, the solid dispersions are an important tool for the pharmaceuti-
cal industry, since they are quite effective in improving solubility, dissolution and bioavailability of drugs. 
Although some aspects still require further improvement, related to the transposition for large-scale produc-
tion and the physicochemical stability of systems, new carrier materials and manufacturing processes have 
been studied to overcome such limitations, which may increase the number of products solid dispersion-
based on the market. Finally, it is worth noting that although the main focus of this work has been the imme-
diate-release solid dispersions, the technique can also be applied to modify the drug release through proper 
selection of carrier materials and excipients. This approach has opened room for the expansion of solid dis-
persion technology in order to obtain sustained-release drug delivery systems. 
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